Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $18.9 million.

  • Rapid Micro Biosystems' Cash & Equivalents fell 1405.37% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year decrease of 1405.37%. This contributed to the annual value of $16.9 million for FY2024, which is 3036.44% down from last year.
  • Latest data reveals that Rapid Micro Biosystems reported Cash & Equivalents of $18.9 million as of Q3 2025, which was down 1405.37% from $18.3 million recorded in Q2 2025.
  • Rapid Micro Biosystems' 5-year Cash & Equivalents high stood at $219.6 million for Q3 2021, and its period low was $16.9 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $51.1 million, with a median of $25.1 million in 2022.
  • As far as peak fluctuations go, Rapid Micro Biosystems' Cash & Equivalents surged by 49306.16% in 2021, and later crashed by 8823.62% in 2022.
  • Over the past 5 years, Rapid Micro Biosystems' Cash & Equivalents (Quarter) stood at $178.4 million in 2021, then tumbled by 84.83% to $27.1 million in 2022, then fell by 10.27% to $24.3 million in 2023, then crashed by 30.36% to $16.9 million in 2024, then grew by 12.03% to $18.9 million in 2025.
  • Its Cash & Equivalents was $18.9 million in Q3 2025, compared to $18.3 million in Q2 2025 and $18.9 million in Q1 2025.